Exchange: NASDAQ·Updated 01:03 PM EST

MBOT News

News
all
press releases
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Microbot Medical (MBOT) delivered earnings and revenue surprises of 0.00% and -22.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Microbot Medical (MBOT) delivered earnings and revenue surprises of 0.00% and -22.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
PLGO, BLPD, INN, RFIL and MBOT have been added to the Zacks Rank #1 (Strong Buy) List on July 23, 2026.
Zacks
Microbot Medical (MBOT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
Microbot Medical (MBOT) delivered earnings and revenue surprises of +37.50% and -76.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Microbot Medical (NASDAQ:MBOT) will be releasing earnings after the market closes on Wednesday, May 13. (View Earnings Report at...
MarketBeat
COR heads into Q2 earnings with expected steady specialty-driven growth, but customer losses and pricing pressures could temper results.
Zacks
SOLV gears up for Q1 earnings with modest growth expected, margin pressure looming and cost initiatives plus MedSurg momentum shaping results outlook.
Zacks
XRAY heads into Q1 earnings with U.S. softness, tariff pressure and transformation costs weighing on margins as investors watch for signs of stabilization.
Zacks
InnovAge heads into fiscal Q3 earnings with strong growth momentum and margin gains, but seasonal cost pressures and fading Medicaid tailwinds may temper near-term upside.
Zacks
RVTY heads into Q1 earnings with Diagnostics strength and Life Sciences stabilization, but China pressures and weak academic demand may temper near-term growth.
Zacks

Advertisement|Remove ads.